PharmaTech

NOVEMBER 22, 2023

In this episode of Drug Digest, Pharmaceutical Technology’s European/Senior Editor, Felicity Thomas, chats about the biggest trends impacting oral and topical drug delivery and how these trends are impacting the excipient sector with Nick DiFranco and Ashley Rezak from Lubrizol Life Science Health.

Pharmaceutical 52

Pharmaceutical 52

European Pharmaceutical Review

MARCH 10, 2023

Currently, effective topical administration is challenging as the industry aims to prolong drug residence time and guarantee appropriate ocular permeation. How to enhance ocular drug bioavailability One approach to enhance drug bioavailability after topical administration is increasing corneal permeability.

Side effects 80

Side effects Management Leads Safety 80

Pharmaceutical Technology

MAY 26, 2023

Krystal Biotech has received approval from the US Food and Drug Administration for topical gene therapy VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) in adults and in children aged six months and above. Topic sponsors are not involved in the creation of editorial content.

Food and Drug Administration 105

Food and Drug Administration FDA Manufacturing Food 105

Pharmaceutical Technology

JUNE 9, 2023

VEVYE, the development name of which is CyclASol, is a cyclosporine, solubilised solution in a new, water-free excipient. CyclASol is topical anti-inflammatory and immunomodulating ophthalmic drug solution containing 0.1%

Food and Drug Administration 98

Food and Drug Administration FDA Medical science Food 98

Pharmaceutical Technology

APRIL 20, 2023

In the first phase of its training workshops, the Pharmaceutical Innovation Center plans to develop a range of excipients [inactive substances that serve as the vehicle or medium for a drug or other active substance] for controlled release dosage forms, improving their bioavailability, along with formulating orally dispersible and chewable tablets.

Pharmaceutical 52

Pharmaceutical Training Manufacturing Pharma 52

Pharmaceutical Technology

JUNE 10, 2023

It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as chronic migraine, facial wrinkles and muscle disorders. Revance Therapeutics is headquartered in Nashville, Tennessee, the US.

Manufacturing 52

Manufacturing Leads Marketing Patients 52

Pharmaceutical Technology

JUNE 10, 2023

It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as chronic migraine, facial wrinkles and muscle disorders. Revance Therapeutics is headquartered in Nashville, Tennessee, the US.

Manufacturing 52

Manufacturing Leads Marketing Patients 52